Controlled Inflammation Drives Neutrophil-Mediated Precision Drug Delivery in Heterogeneous Tumors

Area of Science:

• Oncology
• Immunology
• Drug Delivery Systems

Background:

• Tumor heterogeneity presents a significant challenge in effective cancer therapy.
• Current targeted therapies often face limitations due to variations within tumors.
• Developing strategies to overcome tumor heterogeneity is crucial for improving treatment outcomes.

Purpose of the Study:

• To present an innovative approach using controlled inflammation for neutrophil-mediated drug delivery.
• To overcome the limitations imposed by tumor heterogeneity in cancer treatment.
• To enhance targeted drug delivery and anti-tumor effects through neutrophil recruitment.

Main Methods:

• Inducing localized tumor inflammation using lipopolysaccharide (LPS).
• Guiding drug-laden neutrophils to tumor sites irrespective of specific tumor markers.
• Mitigating systemic inflammatory responses via neutrophil transfusion.
• Evaluating the therapeutic efficacy in a murine breast cancer model.

Main Results:

• Significantly amplified recruitment of drug-laden neutrophils to tumor sites.
• Enhanced targeted drug delivery and triggered release of neutrophil extracellular traps (NETs).
• Demonstrated mitigation of systemic inflammatory responses, ensuring clinical viability.
• Significant impediment of tumor growth in a murine breast cancer model compared to conventional treatments.

Conclusions:

• Controlled inflammation is a versatile strategy for precise drug delivery across diverse tumor types.
• Neutrophil-mediated drug delivery offers a promising approach to address tumor heterogeneity.
• This method enhances therapeutic efficacy and shows potential for broader clinical application in cancer treatment.